(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection
暂无分享,去创建一个
I. Vranesic | G. Battaglia | M. Maj | V. Bruno | P. Flor | R. Kuhn | T. Stein | Z. Dragic | R. Yamamoto | G. Battaglia | W. Inderbitzin | N. Stoehr | F. Gasparini | F. Nicoletti | R. Kuhn | N. Stoehr | I. Vranesic | M. Maj | V. Bruno | Z. Dragic | R. Yamamoto | G. Battaglia | W. Inderbitzin | T. Stein | F. Gasparini | F. Nicoletti | P. J. Flor | F. Nicoletti | Fabrizio Gasparini | F. Gasparini
[1] F. Gasparini,et al. The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.
[2] M. Behrens,et al. Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures , 1998, The European journal of neuroscience.
[3] D. Choi,et al. 4 – Cytotoxicity in Murine Neocortical Cell Culture , 1993 .
[4] J. Kemp,et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] K. Reymann,et al. Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R,S)‐4‐phosphonophenylglycine , 2000, British Journal of Pharmacology.
[6] K. Maiese,et al. Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection , 2000, Journal of neuroscience research.
[7] P Hiselius,et al. The New Generation , 2021, The Women's Liberation Movement in Russia.
[8] F. Nicoletti,et al. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.
[9] C. Elger,et al. Up‐regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability , 2000, Annals of neurology.
[10] Roland Heckendorn,et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.
[11] F. Gasparini,et al. Selective Activation of mGlu4 Metabotropic Glutamate Receptors Is Protective against Excitotoxic Neuronal Death , 2000, The Journal of Neuroscience.
[12] T. Knöpfel,et al. Profiling of trans-azetidine-2,4-dicarboxylic acid at the human metabotropic glutamate receptors mGlu1b, -2, -4a and -5a. , 1995, European journal of pharmacology.
[13] H. Tse,et al. α-methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists , 1996, Neuropharmacology.
[14] F. Nicoletti,et al. Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] J. Cano,et al. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.
[16] S. D’Mello,et al. Insulin-Like Growth Factor and Potassium Depolarization Maintain Neuronal Survival by Distinct Pathways: Possible Involvement of PI 3-Kinase in IGF-1 Signaling , 1997, The Journal of Neuroscience.
[17] T. Knöpfel,et al. A Novel Splice Variant of a Metabotropic Glutamate Receptor, Human mGluR7b , 1997, Neuropharmacology.
[18] F. Nicoletti,et al. The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.
[19] K. Bales,et al. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 , 1999 .
[20] Scott Nawy,et al. Suppression by glutamate of cGMP-activated conductance in retinal bipolar cells , 1990, Nature.
[21] F. Gasparini,et al. Neuroprotective activity of metabotropic glutamate receptor ligands. , 2002, Advances in experimental medicine and biology.
[22] F. Gasparini,et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.
[23] F. Nicoletti,et al. Molecular determinants of metabotropic glutamate receptor signaling. , 2001, Trends in pharmacological sciences.
[24] J. M. Mathiesen,et al. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB‐1893 and MPEP , 2003, British journal of pharmacology.
[25] E. Meli,et al. 1‐Aminoindan‐1,5‐dicarboxylic acid and (S)‐(+)‐2‐(3′‐carboxybicyclo[1.1.1] pentyl)‐glycine, two mGlu1 receptor‐preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischaemia , 1999, The European journal of neuroscience.
[26] K. Mangano,et al. Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures , 2002, The Journal of Neuroscience.
[27] Ayae Kinoshita,et al. Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus , 1997, The Journal of Neuroscience.
[28] J. Pin,et al. New perspectives for the development of selective metabotropic glutamate receptor ligands. , 1999, European journal of pharmacology.
[29] F. Nicoletti,et al. Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. , 1996, European journal of pharmacology.
[30] S W Scherer,et al. Localization of the human mGluR4 gene within an epilepsy susceptibility locus(1). , 2001, Brain research. Molecular brain research.
[31] R. Shigemoto,et al. mGluR7‐like metabotropic glutamate receptors inhibit NMDA‐mediated excitotoxicity in cultured mouse cerebellar granule neurons , 1999, The European journal of neuroscience.
[32] S. Urwyler,et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. , 2001, Molecular pharmacology.
[33] P. Calabresi,et al. Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission , 2001, Molecular and Cellular Neuroscience.
[34] F. Nicoletti,et al. Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3‐kinase pathways , 2001, Journal of neurochemistry.
[35] A. Caricasole,et al. Native group‐III metabotropic glutamate receptors are coupled to the mitogen‐activated protein kinase/phosphatidylinositol‐3‐kinase pathways , 2002, Journal of neurochemistry.
[36] C. Hsiao,et al. A [35S]GTPγS binding assessment of metabotropic glutamate receptor standards in Chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4 , 1998, Neuropharmacology.
[37] E. Meli,et al. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms , 1999, Neuropharmacology.
[38] F. Gasparini,et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.
[39] D. Hall,et al. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. , 2000, Molecular pharmacology.
[40] T. Knöpfel,et al. The agonist selectivity of a class III metabotropic glutamate receptor, human mGluR4a, is determined by the N-terminal extracellular domain , 1995, Neuroreport.
[41] P. Suzdak,et al. L-2-amino-4-phosphonobutyrate (L-AP4) is an agonist at the type IV metabotropic glutamate receptor which is negatively coupled to adenylate cyclase. , 1993, European journal of pharmacology.
[42] J. Cano,et al. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury , 2002, Neuroscience.
[43] K. Maiese,et al. Activation of the metabotropic glutamate receptor is neuroprotective during nitric oxide toxicity in primary hippocampal neurons of rats , 1995, Neuroscience Letters.
[44] Burton S. Rosner,et al. Neuropharmacology , 1958, Nature.
[45] D. Laurie,et al. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[46] T. Knöpfel,et al. The C‐Terminal Domain of the mGluR1 Metabotropic Glutamate Receptor Affects Sensitivity to Agonists , 1996, Journal of neurochemistry.
[47] J. Penney,et al. The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.
[48] F. Nicoletti,et al. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. , 1995, Molecular pharmacology.
[49] L. Prézeau,et al. A model for the functioning of family 3 GPCRs. , 2002, Trends in pharmacological sciences.
[50] T. Knöpfel,et al. Molecular Cloning, Functional Expression and Pharmacological Characterization of the Human Metabotropic Glutamate Receptor Type 2 , 1995, The European journal of neuroscience.
[51] G. Siggins,et al. Metabotropic glutamate receptors regulate N-methyl-D-aspartate-mediated synaptic transmission in nucleus accumbens. , 1997, Journal of neurophysiology.
[52] R. Tsien,et al. A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.
[53] T. Knöpfel,et al. Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4 , 1995, Neuropharmacology.
[54] F. Nicoletti,et al. Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.
[55] U. Dirnagl,et al. Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage , 2000, Neuropharmacology.
[56] S. Lazareno,et al. Pharmacological characterization of acetylcholine‐stimulated [35S]‐GTPγS binding mediated by human muscarinic m1–m4 receptors: antagonist studies , 1993, British journal of pharmacology.